Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data

Sang Gune K. Yoo, Grace S. Chung, Silver K. Bahendeka, Abla M. Sibai, Albertino Damasceno, Farshad Farzadfar, Peter Rohloff, Corine Houehanou, Bolormaa Norov, Khem B. Karki, Mohammadreza Azangoukhyavy, Maja E. Marcus, Krishna K. Aryal, Luisa C.C. Brant, Michaela Theilmann, Renata Cífková, Nuno Lunet, Mongal S. Gurung, Joseph Kibachio Mwangi, Joao MartinsRosa Haghshenas, Lela Sturua, Sebastian Vollmer, Till Bärnighausen, Rifat Atun, Jeremy B. Sussman, Kavita Singh, Sahar Saeedi Moghaddam, David Guwatudde, Pascal Geldsetzer, Jennifer Manne-Goehler, Mark D. Huffman, Justine I. Davies, David Flood

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

The role of aspirin in the primary prevention of atherosclerotic cardiovascular disease (CVD) is not clear, with recent clinical trials evaluating aspirin for primary prevention demonstrating both modest benefits and risks associated with its use [1]. Aspirin is not routinely recommended for primary prevention of CVD. Understanding patterns of aspirin use can inform strategies to promote guideline-concordant therapy, including de-implementation strategies to reduce unnecessary aspirin use. This study seeks to provide an updated estimate of worldwide aspirin use for primary prevention of CVD.

Original languageEnglish
Article number44
JournalGlobal Heart
Volume9
Issue number1
DOIs
StatePublished - May 3 2024

Keywords

  • aspirin
  • cardiovascular disease
  • noncommunicable disease
  • prevention

Fingerprint

Dive into the research topics of 'Global Prevalence of Aspirin Use for Primary Prevention of Cardiovascular Disease: A Cross-Sectional Study of Nationally Representative, Individual-Level Data'. Together they form a unique fingerprint.

Cite this